According to the sources provided, Cosentyx (secukinumab) is a biologic medication used to treat several conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis.

The first source [1] does not mention any age restrictions for Cosentyx use. However, the second source [2] specifically discusses the use of Cosentyx in pediatric patients with psoriasis. The website states that Cosentyx has been approved by the FDA for use in children aged 6 years and older with moderate to severe plaque psoriasis.

The third source [3] is a prescribing information document provided by the manufacturer, Novartis. According to this document, there are no specific dosage adjustments required for elderly patients. However, it also notes that the safety and effectiveness of Cosentyx in pediatric patients under the age of 18 have not been established for other indications besides moderate to severe plaque psoriasis.

In conclusion, while the sources do not provide a clear answer regarding age restrictions for Cosentyx use, the medication has been approved by the FDA for use in pediatric patients aged 6 years and older with moderate to severe plaque psoriasis. It is important to consult with a healthcare provider to determine if Cosentyx is appropriate for an individual's specific condition and age.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.cosentyx.com/pediatric-psoriasis
[3] https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf